Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

FDA Approves RotaTeq

On Friday, Merck received FDA approval for its new oral rotavirus vaccine, RotaTeq, and will begin domestic distribution within a week. At a cost of $187.50 for the three-dose series, RotaTeq is one of the most expensive vaccines to date; by 2009, the company forecasts that the vaccine could bring in as much as $500 million in annual revenue.

According to the New York Times:

Nuking Malaria

The latest issue of Business 2.0 features an article on Stephen Hoffman and his company Sanaria, which is working to develop a malaria vaccine by irradiating parasite-infected mosquitos.

How Sanaria turns the insects that transmit malaria into incubators for its vaccine: